<DOC>
	<DOCNO>NCT00977353</DOCNO>
	<brief_summary>Major depressive disorder complex disease currently available antidepressant aim monoamine neurotransmission exhibit limited efficacy cognitive effect . N-methyl-D-aspartate ( NMDA ) , one subtype glutamate receptor , play important role learn memory . N-methyl-D-aspartic acid ( NMDA ) enhance agent , sarcosine ( N-methylglycine ) , use adjunctive therapy schizophrenia . Sarcosine improve psychotic also depressive symptom patient schizophrenia . To confirm antidepressant effect , purpose study compare citalopram sarcosine efficacy major depressive patient .</brief_summary>
	<brief_title>N-methylglycine ( Sarcosine ) Treatment Depression</brief_title>
	<detailed_description>Major depressive disorder complex disease currently available antidepressant aim monoamine neurotransmission exhibit limited efficacy cognitive effect . Novel therapy via manipulate neurotransmission ( e.g . glutamate receptor ) develop . NMDA enhance agent , sarcosine demonstrate improve negative symptom depressive symptom schizophrenic patient . The purpose study compare citalopram sarcosine aspect efficacy , safety major depressive patient . In study , 40 major depressive patient recruit 6-week trial randomly assign two group ( 20-60 mg/d citalopram , 500 - 1500 mg/d sarcosine ) double-blind manner . Hamilton Depression Rating Scale ( 17-item ) , CGI ( Clinical Global Impression ) , GAF ( Global Assessment Function ) side effect evaluate every two week trial . The efficacy two group compare .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Aged 1855 year Fulfilled DSMIV criterion major depressive disorder Had 17item Hamilton Rating Scale Depression ( HAMD17 ) &gt; or= 18 No DSMIV diagnosis substance abuse dependence ( include alcohol ) within past 6 month Had drug free &gt; 3 month Physically healthy laboratory parameter within normal limit . Agree participate study provide informed consent Had history epilepsy , head trauma major neurological medical disease Had psychotic depression , bipolar I/II disorder , schizophrenia psychotic disorder Moderatesevere suicidal risk Severe cognitive impairment Female subject pregnant , risk pregnancy lactation Initiating stop formal psychotherapy within six week prior enrollment Had history poor response SSRIs previously receive electroconvulsive therapy Had history severe adverse reaction SSRIs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Sarcosine</keyword>
	<keyword>N-methylglycine</keyword>
	<keyword>NMDA</keyword>
</DOC>